Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

Pair your accounts.

Export articles to Mendeley

Get article recommendations from ACS based on references in your Mendeley library.

You’ve supercharged your research process with ACS and Mendeley!

Click to create an ACS ID

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.

Your Mendeley pairing has expired. Please reconnect
ACS Publications. Most Trusted. Most Cited. Most Read
My Activity

Figure 1Loading Img

Doxorubicin Metabolism and Toxicity in Human Myocardium:  Role of Cytoplasmic Deglycosidation and Carbonyl Reduction

View Author Information
Institutes of Pharmacology and Biochemistry, Catholic University School of Medicine, Rome, Italy, and Department of Drug Sciences, G. D'Annunzio University School of Pharmacy, Chieti, Italy
Cite this: Chem. Res. Toxicol. 2000, 13, 5, 414–420
Publication Date (Web):April 14, 2000
Copyright © 2000 American Chemical Society

    Article Views





    Other access options


    The anthracycline doxorubicin (DOX) is an exceptionally good antineoplastic agent, but its use is limited by formation of metabolites which induce acute and chronic cardiac toxicities. Whereas the acute toxicity is mild, the chronic toxicity can produce a life-threatening cardiomyopathy. Studies in laboratory animals are of limited value in predicting the structure and reactivity of toxic metabolites in humans; therefore, we used an ethically acceptable system which is suitable for exploring DOX metabolism in human myocardium. The system involves cytosolic fractions from myocardial samples obtained during aorto-coronary bypass grafting. After reconstitution with NADPH and DOX, these fractions generate the alcohol metabolite doxorubicinol (DOXol) as well as DOX deoxyaglycone and DOXol hydroxyaglycone, reflecting reduction of the side chain carbonyl group, reductase-type deglycosidation of the anthracycline, and hydrolase-type deglycosidation followed by carbonyl reduction, respectively. The efficiency of each metabolic route has been evaluated at low and high DOX:protein ratios, reproducing acute, single-dose and chronic, multiple-dose regimens, respectively. Low DOX:protein ratios increase the efficiency of formation of DOX deoxyaglycone and DOXol hydroxyaglycone but decrease that of DOXol. Conversely, high DOX:protein ratios facilitate the formation of DOXol but impair reductase- or hydrolase-type deglycosidation and uncouple hydrolysis from carbonyl reduction, making DOXol accumulate at levels higher than those of DOX deoxyaglycone and DOXol hydroxyaglycone. Structure−activity considerations have suggested that aglycones and DOXol may inflict cardiac damage by inducing oxidative stress or by perturbing iron homeostasis, respectively. Having characterized the influence of DOX:protein ratios on deglycosidation or carbonyl reduction, we propose that the benign acute toxicity should be attributed to the oxidant activity of aglycones, whereas the life-threatening chronic toxicity should be attributed to alterations of iron homeostasis by DOXol. This picture rationalizes the limited protective efficacy of antioxidants against chronic cardiomyopathy vis-à-vis the better protection offered by iron chelators, and forms the basis for developing analogues which produce less DOXol.

    Read this article

    To access this article, please review the available access options below.

    Get instant access

    Purchase Access

    Read this article for 48 hours. Check out below using your ACS ID or as a guest.


    Access through Your Institution

    You may have access to this article through your institution.

    Your institution does not have access to this content. You can change your affiliated institution below.

     Institute of Pharmacology, Catholic University School of Medicine.

     Institute of Biochemistry, Catholic University School of Medicine.


     To whom correspondence should be addressed:  Department of Drug Sciences, G. D'Annunzio University School of Pharmacy, Via dei Vestini, 66013 Chieti, Italy. Phone: 011-39-0871-3555237. Fax: 011-39-0871-3555315. E-mail: [email protected].


     G. D'Annunzio University School of Pharmacy.

    Cited By

    This article is cited by 129 publications.

    1. Jyotsnamayee Nayak, Ashita Sood, Mahesh Kulharia, Suban K. Sahoo, Rajender Kumar. Structural Distortion of β-Cyclodextrin Plays a Key Role in the pH-dependent Host–Guest Chemistry with Doxorubicin, Evident by the Electrochemical and Molecular Dynamics Approach. Journal of Chemical Information and Modeling 2023, 63 (10) , 2975-2982.
    2. Upashi Goswami, Raghuram Kandimalla, Sanjeeb Kalita, Arun Chattopadhyay, Siddhartha Sankar Ghosh. Polyethylene Glycol-Encapsulated Histone Deacetylase Inhibitor Drug-Composite Nanoparticles for Combination Therapy with Artesunate. ACS Omega 2018, 3 (9) , 11504-11516.
    3. Sebastian Imstepf, Vanessa Pierroz, Paula Raposinho, Matthias Bauwens, Michael Felber, Thomas Fox, Adam B. Shapiro, Robert Freudenberg, Célia Fernandes, Sofia Gama, Gilles Gasser, Felix Motthagy, Isabel R. Santos, and Roger Alberto . Nuclear Targeting with an Auger Electron Emitter Potentiates the Action of a Widely Used Antineoplastic Drug. Bioconjugate Chemistry 2015, 26 (12) , 2397-2407.
    4. Vera Marisa Costa, Félix Carvalho, José Alberto Duarte, Maria de Lourdes Bastos, and Fernando Remião . The Heart As a Target for Xenobiotic Toxicity: The Cardiac Susceptibility to Oxidative Stress. Chemical Research in Toxicology 2013, 26 (9) , 1285-1311.
    5. Olga Swiech, Anna Mieczkowska, Kazimierz Chmurski, and Renata Bilewicz . Intermolecular Interactions between Doxorubicin and β-Cyclodextrin 4-Methoxyphenol Conjugates. The Journal of Physical Chemistry B 2012, 116 (6) , 1765-1771.
    6. Praveena Mohan and Natalya Rapoport. Doxorubicin as a Molecular Nanotheranostic Agent: Effect of Doxorubicin Encapsulation in Micelles or Nanoemulsions on the Ultrasound-Mediated Intracellular Delivery and Nuclear Trafficking. Molecular Pharmaceutics 2010, 7 (6) , 1959-1973.
    7. Joseph B. Katzenmeyer, Christopher V. Eddy, and Edgar A. Arriaga. Tandem Laser-Induced Fluorescence and Mass Spectrometry Detection for High-Performance Liquid Chromatography Analysis of the in Vitro Metabolism of Doxorubicin. Analytical Chemistry 2010, 82 (19) , 8113-8120.
    8. Xiangshan Li, Ragini Singh, Bingyuan Zhang, Santosh Kumar, Guoru Li. Development of a biophotonic fiber sensor using direct-taper and anti-taper techniques with seven-core and four-core fiber for the detection of doxorubicin in cancer treatment. Optics Express 2024, 32 (10) , 17239.
    9. Ana Reis-Mendes, Cláudia Vitorino-Oliveira, Mariana Ferreira, Félix Carvalho, Fernando Remião, Emília Sousa, Maria de Lourdes Bastos, Vera Marisa Costa. Comparative In Vitro Study of the Cytotoxic Effects of Doxorubicin’s Main Metabolites on Cardiac AC16 Cells Versus the Parent Drug. Cardiovascular Toxicology 2024, 24 (3) , 266-279.
    10. Nilesh Kumar Sharma, Anjali Bahot, Gopinath Sekar, Mahima Bansode, Kratika Khunteta, Priyanka Vijay Sonar, Ameya Hebale, Vaishnavi Salokhe, Birandra Kumar Sinha. Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review. Cancers 2024, 16 (4) , 680.
    11. S. Malathi, Valappil Sisila, V. Singaravel, Nandakumar Venkatesan, Iqbal Pakrudheen, R. Dhanaraj, Niraikulam Ayyadurai, V. Bhuvarahamurthy, S. Narayana Kalkura. Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy. Materials Advances 2023, 4 (21) , 5224-5237.
    12. Nicoletta Bertorello, Roberto Luksch, Gianni Bisogno, Riccardo Haupt, Paolo Spallarossa, Rosita Cenna, Franca Fagioli. Cardiotoxicity in children with cancer treated with anthracyclines: A position statement on dexrazoxane. Pediatric Blood & Cancer 2023, 70 (9)
    13. Akshoo Rathi, Yogender Bahugana, Mohit Nagar. An Overview on Cardio-Protective Compound Dexrazoxane. International Journal Of Health Care And Nursing 2023, 2 (1) , 01-12.
    14. Janthima Methaneethorn, Kanokkan Tengcharoen, Nattawut Leelakanok, Rowan AlEjielat. Population pharmacokinetics of doxorubicin: A systematic review. Asia-Pacific Journal of Clinical Oncology 2023, 19 (1) , 9-26.
    15. Carmen Avendaño, J. Carlos Menéndez. Anticancer strategies involving radical species. 2023, 165-235.
    16. Kaiqiang Liu, Jian Zhang, Xinxin Li, Yingying Xie, Yong Li, Xu Wang, Xiaoyun Jiao, Xilei Xie, Bo Tang. Hypochlorous acid-activated two-photon fluorescent probe for evaluation of anticancer drug-induced cardiotoxicity and screening of antioxidant drugs. Organic Chemistry Frontiers 2022, 9 (24) , 6795-6801.
    17. Goutam Pramanik, Soumabha Bag, Sabyasachi Chakrabortty. Fluorescent nanodiamond for nanotheranostic applications. Microchimica Acta 2022, 189 (12)
    18. Isobel C Jones, Crispin R Dass. Doxorubicin-induced cardiotoxicity: causative factors and possible interventions. Journal of Pharmacy and Pharmacology 2022, 74 (12) , 1677-1688.
    19. Margo Waters, Juliane Hopf, Emma Tam, Stephanie Wallace, Jordan Chang, Zach Bennett, Hadrian Aquino, Ryan Roeder, Paul Helquist, M. Stack, Prakash Nallathamby. Biocompatible, Multi-Mode, Fluorescent, T2 MRI Contrast Magnetoelectric-Silica Nanoparticles (MagSiNs), for On-Demand Doxorubicin Delivery to Metastatic Cancer Cells. Pharmaceuticals 2022, 15 (10) , 1216.
    20. Dalia O. Saleh, Sawsan S. Mahmoud, Azza Hassan, Eman F. Sanad. Doxorubicin-induced hepatic toxicity in rats: Mechanistic protective role of Omega-3 fatty acids through Nrf2/HO-1 activation and PI3K/Akt/GSK-3β axis modulation. Saudi Journal of Biological Sciences 2022, 29 (7) , 103308.
    21. Rachel E. Nicoletto, Clyde M. Ofner. Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells. Cancer Chemotherapy and Pharmacology 2022, 89 (3) , 285-311.
    22. Lara Zorić, Nikša Drinković, Vedran Micek, Leo Frkanec, Akif Emre Türeli, Nazende Günday-Türeli, Ivana Vinković Vrček, Ruža Frkanec. High-Throughput Method for the Simultaneous Determination of Doxorubicin Metabolites in Rat Urine after Treatment with Different Drug Nanoformulations. Molecules 2022, 27 (4) , 1177.
    23. James Akingbasote, Sandra Szlapinski, Elora Hilmas, Patrik Miller, Natalie Rine. Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites. 2022, 197-232.
    24. Edozie S. Okpara, Isaac A. Adedara, Xiaohua Guo, Matthew L. Klos, Ebenezer O. Farombi, Shuxin Han. Molecular mechanisms associated with the chemoprotective role of protocatechuic acid and its potential benefits in the amelioration of doxorubicin-induced cardiotoxicity: A review. Toxicology Reports 2022, 9 , 1713-1724.
    25. N.S. Sumitha, S. Sreeja, P.J. George Varghese, G.S. Sailaja. A dual functional superparamagnetic system with pH-dependent drug release and hyperthermia potential for chemotherapeutic applications. Materials Chemistry and Physics 2021, 273 , 125108.
    26. Sabina Y. van der Zanden, Xiaohang Qiao, Jacques Neefjes. New insights into the activities and toxicities of the old anticancer drug doxorubicin. The FEBS Journal 2021, 288 (21) , 6095-6111.
    27. Sruthi Sritharan, Nageswaran Sivalingam. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sciences 2021, 278 , 119527.
    28. Elizabeth A. Wilson, Nahid Sultana, Khyati N. Shah, Howard L. Elford, Jesika S. Faridi. Molecular Targeting of RRM2, NF-κB, and Mutant TP53 for the Treatment of Triple-Negative Breast Cancer. Molecular Cancer Therapeutics 2021, 20 (4) , 655-664.
    29. Tanaya R. Vaidya, Hardik Mody, Yesenia L. Franco, Ashley Brown, Sihem Ait-Oudhia. Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity. The AAPS Journal 2021, 23 (1)
    30. Tarek Magdy, Paul W Burridge. Use of Hipsc to Explicate Genomic Predisposition to AnthrAcycline-Induced Cardiotoxicity. Pharmacogenomics 2021, 22 (1) , 41-54.
    31. Nawal A. Alarfaj, Maha F. El-Tohamy. New Functionalized Polymeric Sensor Based NiO/MgO Nanocomposite for Potentiometric Determination of Doxorubicin Hydrochloride in Commercial Injections and Human Plasma. Polymers 2020, 12 (12) , 3066.
    32. Shian-Ren Lin, Chun-Shu Lin, Ching-Cheng Chen, Feng-Jen Tseng, Tsung-Jui Wu, Lebin Weng, Ching-Feng Weng. Doxorubicin metabolism moderately attributes to putative toxicity in prodigiosin/doxorubicin synergism in vitro cells. Molecular and Cellular Biochemistry 2020, 475 (1-2) , 119-126.
    33. Sameena Mehtab, M G H Zaidi, Pragati Joshi, Deependra Bawari. Synthesis and characterization of barium titanate/polyacrylonitrile nanocomposite for electrochemical sensing of doxorubicin. IOP SciNotes 2020, 1 (3) , 034201.
    34. Christian Siebel, Claudia Lanvers-Kaminsky, Gudrun Würthwein, Georg Hempel, Joachim Boos. Bioanalysis of doxorubicin aglycone metabolites in human plasma samples–implications for doxorubicin drug monitoring. Scientific Reports 2020, 10 (1)
    35. Le Chen, Lin Li. Aminocaproylated nanodiamond prodrug for tumor intracellular enhanced delivery of doxorubicin. Journal of Drug Delivery Science and Technology 2020, 60 , 102017.
    36. Dalia Saleh, Marawan Abdelbaset, Azza Hassan, Ola Sharaf, Sawsan Mahmoud, Rehab Hegazy, . Omega-3 fatty acids ameliorate doxorubicin-induced cardiorenal toxicity: In-vivo regulation of oxidative stress, apoptosis and renal Nox4, and in-vitro preservation of the cytotoxic efficacy. PLOS ONE 2020, 15 (11) , e0242175.
    37. Majid Pakdel, Heidar Raissi, Mahnaz Shahabi. Predicting doxorubicin drug delivery by single-walled carbon nanotube through cell membrane in the absence and presence of nicotine molecules: a molecular dynamics simulation study. Journal of Biomolecular Structure and Dynamics 2020, 38 (5) , 1488-1498.
    38. Won-Gu Choi, Dong Kyun Kim, Yongho Shin, Ria Park, Yong-Yeon Cho, Joo Young Lee, Han Chang Kang, Hye Suk Lee. Liquid Chromatography–Tandem Mass Spectrometry for the Simultaneous Determination of Doxorubicin and its Metabolites Doxorubicinol, Doxorubicinone, Doxorubicinolone, and 7-Deoxydoxorubicinone in Mouse Plasma. Molecules 2020, 25 (5) , 1254.
    39. Natasha Irrera, Giovanni Pallio, Federica Mannino, Rosario Gugliotta, Daniela Metro, Domenica Altavilla, Francesco Squadrito. Administration of a Nutraceutical Mixture Composed by Aloe arborescens , Annona muricata , Morinda citrifolia , Beta rubra , Scutellaria baicalensis , and Vaccinium myrtillus Reduces Doxorubicin-Induced Side Effects. Nutrition and Cancer 2020, 72 (2) , 343-351.
    40. Anais Audebrand, Laurent Désaubry, Canan G. Nebigil. Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments. Frontiers in Cardiovascular Medicine 2020, 6
    41. Anchit Bhagat, Eugenie S. Kleinerman. Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. 2020, 181-192.
    42. Xu Wang, Renjie Hui, Yun Chen, Wentao Wang, Yujiao Chen, Xiaohai Gong, Jian Jin. Discovery of Novel Doxorubicin Metabolites in MCF7 Doxorubicin-Resistant Cells. Frontiers in Pharmacology 2019, 10
    43. O. O. Shevchuk. ЕФЕКТИ ЕНТЕРОСОРБЦІЇ ТА ФІЛГРАСТИМУ ПРИ СУБХРОНІЧНІЙ ДОКСОРУБІЦИНОВІЙ ТОКСИЧНОСТІ. Здобутки клінічної і експериментальної медицини 2019, (3) , 146-156.
    44. Nadine Wenningmann, Merle Knapp, Anusha Ande, Tanaya R. Vaidya, Sihem Ait-Oudhia. Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring. Molecular Pharmacology 2019, 96 (2) , 219-232.
    45. Ana Reis-Mendes, Félix Carvalho, Fernando Remião, Emília Sousa, Maria de Lourdes Bastos, Vera Marisa Costa. The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. Biomolecules 2019, 9 (3) , 98.
    46. Shubhmita Bhatnagar, Neha Gajanan Bankar, Mrunal Vijay Kulkarni, Venkata Vamsi Krishna Venuganti. Dissolvable microneedle patch containing doxorubicin and docetaxel is effective in 4T1 xenografted breast cancer mouse model. International Journal of Pharmaceutics 2019, 556 , 263-275.
    47. Caroline Manto Chagas, Sara Moss, Laleh Alisaraie. Drug metabolites and their effects on the development of adverse reactions: Revisiting Lipinski’s Rule of Five. International Journal of Pharmaceutics 2018, 549 (1-2) , 133-149.
    48. Meetal Solanki, Amy Pointon, Barry Jones, Karl Herbert. Cytochrome P450 2J2: Potential Role in Drug Metabolism and Cardiotoxicity. Drug Metabolism and Disposition 2018, 46 (8) , 1053-1065.
    49. Evelyn C. da S. Santos, Amanda Watanabe, Maria D. Vargas, Marcelo N. Tanaka, Flavio Garcia, Célia M. Ronconi. AMF-responsive doxorubicin loaded β-cyclodextrin-decorated superparamagnetic nanoparticles. New Journal of Chemistry 2018, 42 (1) , 671-680.
    50. Rubén Ruiz-González, Paula Milán, Roger Bresolí-Obach, Juan Stockert, Angeles Villanueva, Magdalena Cañete, Santi Nonell. Photodynamic Synergistic Effect of Pheophorbide a and Doxorubicin in Combined Treatment against Tumoral Cells. Cancers 2017, 9 (12) , 18.
    51. Agata Krzak, Olga Swiech, Maciej Majdecki, Renata Bilewicz. Complexing daunorubicin with β-cyclodextrin derivative increases drug intercalation into DNA. Electrochimica Acta 2017, 247 , 139-148.
    52. Ivanna Hrynchak, Emília Sousa, Madalena Pinto, Vera Marisa Costa. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. Drug Metabolism Reviews 2017, 49 (2) , 158-196.
    53. Mariana Seke, Danijela Petrovic, Aleksandar Djordjevic, Danica Jovic, Milica Labudovic Borovic, Zdenko Kanacki, Milan Jankovic. Fullerenol/doxorubicin nanocomposite mitigates acute oxidative stress and modulates apoptosis in myocardial tissue. Nanotechnology 2016, 27 (48) , 485101.
    54. Tarek Magdy, Brian T. Burmeister, Paul W. Burridge. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?. Pharmacology & Therapeutics 2016, 168 , 113-125.
    55. Fahad Al-Abbasi, Eman Alghamdi, Mohammed Baghdadi, Abdulmohsin Alamoudi, Ali El-Halawany, Hany El-Bassossy, Ali Aseeri, Ahmed Al-Abd. Gingerol Synergizes the Cytotoxic Effects of Doxorubicin against Liver Cancer Cells and Protects from Its Vascular Toxicity. Molecules 2016, 21 (7) , 886.
    56. Vikrant Vijay, Carrie L. Moland, Tao Han, James C. Fuscoe, Taewon Lee, Eugene H. Herman, G. Ronald Jenkins, Sherry M. Lewis, Connie A. Cummings, Yuan Gao, Zhijun Cao, Li-Rong Yu, Varsha G. Desai. Early transcriptional changes in cardiac mitochondria during chronic doxorubicin exposure and mitigation by dexrazoxane in mice. Toxicology and Applied Pharmacology 2016, 295 , 68-84.
    57. Brenda Loaiza, Salomon Hernández-Gutierrez, Juan Jose Montesinos, Mahara Valverde, Emilio Rojas. Nuclear Transcription Factor Kappa B Downregulation Reduces Chemoresistance in Bone Marrow-derived Cells Through P-glycoprotein Modulation. Archives of Medical Research 2016, 47 (2) , 78-88.
    58. Jan Hintzpeter, Jan Moritz Seliger, Jakub Hofman, Hans-Joerg Martin, Vladimir Wsol, Edmund Maser. Inhibition of human anthracycline reductases by emodin — A possible remedy for anthracycline resistance. Toxicology and Applied Pharmacology 2016, 293 , 21-29.
    59. Masoumeh Taei, Foroozan Hasanpour, Hossein Salavati, Shekofeh Mohammadian. Fast and sensitive determination of doxorubicin using multi-walled carbon nanotubes as a sensor and CoFe2O4 magnetic nanoparticles as a mediator. Microchimica Acta 2016, 183 (1) , 49-56.
    60. Olga Swiech, Maciej Majdecki, Aleksander Debinski, Agata Krzak, Tomasz M. Stępkowski, Grzegorz Wójciuk, Marcin Kruszewski, Renata Bilewicz. Competition between self-inclusion and drug binding explains the pH dependence of the cyclodextrin drug carrier – molecular modelling and electrochemistry studies. Nanoscale 2016, 8 (37) , 16733-16742.
    61. Lin Li, Lu Tian, Yongli Wang, Wenjing Zhao, Fangqin Cheng, Yingqi Li, Binsheng Yang. Smart pH-responsive and high doxorubicin loading nanodiamond for in vivo selective targeting, imaging, and enhancement of anticancer therapy. Journal of Materials Chemistry B 2016, 4 (29) , 5046-5058.
    62. Masoumeh Taei, Foroozan Hasanpour, Elaheh Dehghani. Electrodepositing of copper nanowires on layered double hydroxide film modified glassy carbon electrode for the determination of doxorubicin. Journal of the Taiwan Institute of Chemical Engineers 2015, 54 , 183-190.
    63. Weiguo Xu, Jianxun Ding, Chunsheng Xiao, Lingyu Li, Xiuli Zhuang, Xuesi Chen. Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic. Biomaterials 2015, 54 , 72-86.
    64. Jan Hintzpeter, Jan Hornung, Bettina Ebert, Hans-Jörg Martin, Edmund Maser. Curcumin is a tight-binding inhibitor of the most efficient human daunorubicin reductase – Carbonyl reductase 1. Chemico-Biological Interactions 2015, 234 , 162-168.
    65. Gustav Holmgren, Jane Synnergren, Yalda Bogestål, Caroline Améen, Karolina Åkesson, Sandra Holmgren, Anders Lindahl, Peter Sartipy. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells. Toxicology 2015, 328 , 102-111.
    66. Carmen Avendaño, J. Carlos Menéndez. Anticancer Drugs Acting via Radical Species. 2015, 133-195.
    67. Mirta R. Alcaráz, Agustina V. Schenone, María J. Culzoni, Héctor C. Goicoechea. Modeling of second-order spectrophotometric data generated by a pH-gradient flow injection technique for the determination of doxorubicin in human plasma. Microchemical Journal 2014, 112 , 25-33.
    68. Nengxuan Ma, Lin Zhang, Ruijin Li, Yehong Zhou, Zongwei Cai, Chuan Dong, Shaomin Shuang. Magnetic solid-phase extraction based on a trimethylstearylammonium bromide coated Fe 3 O 4 /SiO 2 composite for determination of adriamycin hydrochloride in human plasma and urine by HPLC-FLD. Anal. Methods 2014, 6 (17) , 6736-6744.
    69. Onkar S. Bains, András Szeitz, Joanna M. Lubieniecka, Gina E. Cragg, Thomas A. Grigliatti, K. Wayne Riggs, Ronald E. Reid. A Correlation between Cytotoxicity and Reductase-Mediated Metabolism in Cell Lines Treated with Doxorubicin and Daunorubicin. Journal of Pharmacology and Experimental Therapeutics 2013, 347 (2) , 375-387.
    70. Ahmed M. Al-Abd, Fahad A. Al-Abbasi, Gihan F. Asaad, Ashraf B. Abdel-Naim. Didox potentiates the cytotoxic profile of doxorubicin and protects from its cardiotoxicity. European Journal of Pharmacology 2013, 718 (1-3) , 361-369.
    71. Sigrid Baumgarten, Ron C. Gaba, Richard B. van Breemen. Confirmation of drug delivery after liver chemoembolization: direct tissue doxorubicin measurement by UHPLC‐MS‐MS. Biomedical Chromatography 2012, 26 (12) , 1529-1533.
    72. Erin L. Westman, Marc J. Canova, Inas J. Radhi, Kalinka Koteva, Inga Kireeva, Nicholas Waglechner, Gerard D. Wright. Bacterial Inactivation of the Anticancer Drug Doxorubicin. Chemistry & Biology 2012, 19 (10) , 1255-1264.
    73. Ali Mokhtar Mahmoud, Ahmed M. Al-Abd, David A. Lightfoot, Hany A. El-Shemy. Anti-cancer characteristics of mevinolin against three different solid tumor cell lines was not solely p53-dependent. Journal of Enzyme Inhibition and Medicinal Chemistry 2012, 27 (5) , 673-679.
    74. Jinhui Xu, Yuan Liu, Ying Yu, Qingjiang Ni, Yun Chen. Subcellular Quantification of Doxorubicin and Its Metabolite in Cultured Human Leukemia Cells Using Liquid Chromatography-Tandem Mass Spectrometry. Analytical Letters 2012, 45 (14) , 1980-1994.
    75. Ja-an Annie Ho, Nien-chu Fan, Amily Fang-ju Jou, Li-chen Wu, Tai-ping Sun. Monitoring the subcellular localization of doxorubicin in CHO-K1 using MEKC−LIF: Liposomal carrier for enhanced drug delivery. Talanta 2012, 99 , 683-688.
    76. Megan M. Freeland, Jackeline Angulo, Alison L. Davis, Adam M. Flook, Brittany L. Garcia, Nathan A. King, Samuelle K. Mangibin, Kristin M. Paul, Megan E. Prosser, Nicole Sata, Jim L. Bentley, Lisa E. Olson. Sex differences in improved efficacy of doxorubicin chemotherapy in Cbr1+/− mice. Anti-Cancer Drugs 2012, 23 (6) , 584-589.
    77. V. Escudero-Ortiz, A. Ramón-López, M.a J. Duart, J.J. Pérez-Ruixo, B. Valenzuela. Farmacocinética poblacional de doxorubicina aplicada a la personalización de su dosificación en pacientes oncológicos. Farmacia Hospitalaria 2012, 36 (4) , 282-291.
    78. Alvaro Mordente, Elisabetta Meucci, Andrea Silvestrini, Giuseppe Ettore Martorana, Bruno Giardina. Anthracyclines and Mitochondria. 2012, 385-419.
    79. A. M. Al-Abd, A. M. Mahmoud, G. A. El-Sherbiny, M. A. El-Moselhy, S. M. Nofal, H. A. El-Latif, W. I. El-Eraky, H. A. El-Shemy. Resveratrol enhances the cytotoxic profile of docetaxel and doxorubicin in solid tumour cell lines in vitro. Cell Proliferation 2011, 44 (6) , 591-601.
    80. Yaohua Wang, Joseph B. Katzenmeyer, Edgar A. Arriaga. Combination of Micellar Electrokinetic and High-Performance Liquid Chromatographies to Assess Age-Related Changes in the In Vitro Metabolism of Fischer 344 Rat Liver. The Journals of Gerontology: Series A 2011, 66A (9) , 935-943.
    81. Adam Skarka, Lucie Škarydová, Hana Štambergová, Vladimír Wsól. Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chemico-Biological Interactions 2011, 191 (1-3) , 66-74.
    82. Pei-Lin Lu, Yi-Chun Chen, Ta-Wei Ou, Hung-Hao Chen, Hsieh-Chih Tsai, Chih-Jen Wen, Chun-Liang Lo, Shiaw-Pyng Wey, Kun-Ju Lin, Tzu-Chen Yen, Ging-Ho Hsiue. Multifunctional hollow nanoparticles based on graft-diblock copolymers for doxorubicin delivery. Biomaterials 2011, 32 (8) , 2213-2221.
    83. Eryun Yan, Yilong Fu, Xue Wang, Yin Ding, Hanqing Qian, Chi-Hwa Wang, Yong Hu, Xiqun Jiang. Hollow chitosan–silica nanospheres for doxorubicin delivery to cancer cells with enhanced antitumor effect in vivo. Journal of Materials Chemistry 2011, 21 (9) , 3147.
    84. Xing-Chen Peng, Feng-Ming Gong, Meng Wei, Xi Chen, Ye Chen, Ke Cheng, Feng Gao, Feng Xu, Feng Bi, Ji-Yan Liu. Proteomic analysis of cell lines to identify the irinotecan resistance proteins. Journal of Biosciences 2010, 35 (4) , 557-564.
    85. Ze Fu, Jiabin Guo, Li Jing, Ruisheng Li, Tingfen Zhang, Shuangqing Peng. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. Toxicology in Vitro 2010, 24 (6) , 1584-1591.
    86. Vijay Kumar Sripuram, Harish K. Kaushik, Satish K. Bedada, Narasimha Y. Reddy, Kiran Kumar Vangara, S. Praneeth Kumar, G. IndiraPriyadarshini, Krishna R. Devarakonda. Development and validation of rapid and sensitive HPLC method for the quantitative determination of doxorubicin in human plasma. Clinical Research and Regulatory Affairs 2010, 27 (3) , 75-81.
    87. Weixue Huang, Liya Ding, Qiang Huang, Hairong Hu, Shan Liu, Xianmei Yang, Xiaohui Hu, Yongjun Dang, Suqin Shen, Jie Li, Xiaona Ji, Songmin Jiang, Jun O. Liu, Long Yu. Carbonyl reductase 1 as a novel target of (−)-epigallocatechin gallate against hepatocellular carcinoma. Hepatology 2010, 52 (2) , 703-714.
    88. Kumiko Sakai-Kato, Eiko Saito, Keiko Ishikura, Toru Kawanishi. Analysis of intracellular doxorubicin and its metabolites by ultra-high-performance liquid chromatography. Journal of Chromatography B 2010, 878 (19) , 1466-1470.
    89. Onkar S. Bains, Morgan J. Karkling, Joanna M. Lubieniecka, Thomas A. Grigliatti, Ronald E. Reid, K. Wayne Riggs. Naturally Occurring Variants of Human CBR3 Alter Anthracycline In Vitro Metabolism. Journal of Pharmacology and Experimental Therapeutics 2010, 332 (3) , 755-763.
    90. Ahmed M. Al-Abd, Ki-Yun Hong, Soo-Chang Song, Hyo-Jeong Kuh. Pharmacokinetics of doxorubicin after intratumoral injection using a thermosensitive hydrogel in tumor-bearing mice. Journal of Controlled Release 2010, 142 (1) , 101-107.
    91. Yunfang Zhang, Haitham El-Sikhry, Ketul R. Chaudhary, Sri Nagarjun Batchu, Anooshirvan Shayeganpour, Taibeh Orujy Jukar, J. Alyce Bradbury, Joan P. Graves, Laura M. DeGraff, Page Myers, Douglas C. Rouse, Julie Foley, Abraham Nyska, Darryl C. Zeldin, John M. Seubert. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. American Journal of Physiology-Heart and Circulatory Physiology 2009, 297 (1) , H37-H46.
    92. Onkar S. Bains, Morgan J. Karkling, Thomas A. Grigliatti, Ronald E. Reid, K. Wayne Riggs. Two Nonsynonymous Single Nucleotide Polymorphisms of Human Carbonyl Reductase 1 Demonstrate Reduced in Vitro Metabolism of Daunorubicin and Doxorubicin. Drug Metabolism and Disposition 2009, 37 (5) , 1107-1114.
    93. Ahmed M. Al-Abd, Nam Ho Kim, Soo-Chang Song, Seung Jin Lee, Hyo-Jeong Kuh. A simple HPLC method for doxorubicin in plasma and tissues of nude mice. Archives of Pharmacal Research 2009, 32 (4) , 605-611.
    94. Ryan H. Takahashi, Onkar S. Bains, Tom A. Pfeifer, Thomas A. Grigliatti, Ronald E. Reid, K. Wayne Riggs. Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro. Drug Metabolism and Disposition 2008, 36 (6) , 991-994.
    95. Onkar S. Bains, Ryan H. Takahashi, Tom A. Pfeifer, Thomas A. Grigliatti, Ronald E. Reid, K. Wayne Riggs. Two Allelic Variants of Aldo-Keto Reductase 1A1 Exhibit Reduced in Vitro Metabolism of Daunorubicin. Drug Metabolism and Disposition 2008, 36 (5) , 904-910.
    96. Carmen Avendaño, J. Carlos Menéndez. Anticancer Drugs Acting via Radical Species, Photosensitizers and Photodynamic Therapy of Cancer. 2008, 93-138.
    97. María Castro‐Puyana, Antonio L. Crego, María L. Marina. Recent advances in the analysis of antibiotics by CE and CEC. ELECTROPHORESIS 2008, 29 (1) , 274-293.
    98. Mariann Plebuch, Michael Soldan, Christoph Hungerer, Lutz Koch, Edmund Maser. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Letters 2007, 255 (1) , 49-56.
    99. W.H. Gotlieb, I. Bruchim, G. Ben-Baruch, B. Davidson, A. Zeltser, A. Andersen, H. Olsen. Doxorubicin levels in the serum and ascites of patients with ovarian cancer. European Journal of Surgical Oncology (EJSO) 2007, 33 (2) , 213-215.
    100. Pierantonio Menna, Emanuela Salvatorelli, Luca Gianni, Giorgio Minotti. Anthracycline Cardiotoxicity. 2007, 21-44.
    Load all citations